SEE WHY GANFORT®
MAY BE THE RIGHT OPTION FOR
YOUR PATIENT
GANFORT® (bimatoprost/timolol ophthalmic solution)
GANFORT® is indicated for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogs.GAN[B]
GANFORT® UD (bimatoprost/timolol ophthalmic solution 0.03/0.5%)
GANFORT® is a fixed-combination therapy of two active substances: bimatoprost, a synthetic prostamide, and timolol, a β-blockerGAN[C]
GANFORT® offers a dual mechanism of actionGAN[E,F]
Bimatoprost and timolol, the two active substances in GANFORT®, decrease elevated intraocular pressure by complementary mechanisms of action, and the combined effect results in additional IOP reduction compared to either compound administered alone. GANFORT® also has a rapid onset of action.GAN[C]
GANFORT® delivers two complementary IOP-lowering modes of actions with the convenience of a single fixed doseGAN[C]
BimatoprostGAN[K], BIM[A]
TimololGAN[K], TIM[B]
1 – Stimulates aqueous humor outflow via the trabecular meshwork and uveoscleral pathways
2 – Possibly reduces aqueous humor formation. The precise mode of action of timolol is unknownGAN[L]
Adapted from GANFORT® Summary of Product Characteristics 2022, NCBI PubChem Bimatoprost Compound Summary, and NCBI PubChem Timolol Compound Summary.GAN[C],BIM[A,B],TIM[A,B]
Administration and dosing for GANFORT®
GANFORT® combines bimatoprost 0.03% and timolol 0.5% in a single bottle for one drop a day.GAN[D]
The recommended dose is one drop of GANFORT® in the affected eye(s) once daily, administered either in the morning or in the evening.GAN[D]
It should be administered at the same time each day.GAN[D]
Since multiple topical treatments may reduce adherence and increase exposure to preservatives, fixed combination therapy such as GANFORT® is preferable to two separate instillations of agents.EGS[A]
GANFORT® is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogs.GAN[B]
GANFORT® may not be suitable for some of your patients
GANFORT® has several contraindications:GAN[I,J]
Hypersensitivity to any of the following:
• Bimatoprost and/or timolol
• Benzalkonium chloride
• Sodium chloride
• Sodium phosphate dibasic heptahydrate
• Citric acid monohydrate
• Hydrochloric acid or sodium hydroxide (to adjust pH)
Purified water
Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease.
Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block, not controlled with pace-maker. Overt cardiac failure, cardiogenic shock.
Please refer to GANFORT® Summary of Product Characteristics for full safety information and precautions for use.
GANFORT is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogs.GAN[B]
The majority of adverse reactions reported in clinical studies using GANFORT were ocular, mild in severity and none were serious. Based on 12-month clinical data, the most commonly reported adverse reaction was conjunctival hyperaemia (mostly trace to mild and thought to be of a non-inflammatory nature) in approximately 26% of patients and led to discontinuation in 1.5% of patients.GAN[E]
Please refer to GANFORT® Summary of Product Characteristics for further information on adverse events.
IOP, intraocular pressure.
GAN - GANFORT® (bimatoprost/timolol ophthalmic solution 0.03%/0.5%). Summary of Product Characteristics. 2022.
BIM – Bimatoprost Compound Summary. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Timolol. Accessed February 2024.
TIM – Timolol Compound Summary. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Timolol. Accessed February 2024.
EGS – European Glaucoma Society (EGS). Terminology and Guidelines for Glaucoma. Fifth edition. EGS. 2020.